News & Investors
News
Lumicell Supports Stand Up To Cancer Dream Team for Early Detection of Gastric Cancer with Investigational Device and New Drug
Global Team Will Launch Gastric Cancer Prevention Clinical Trial. CAUTION – Investigational device and new drug. Limited by Federal (or United States) law to investigational use.
- Los Angeles
- January 8, 2026
Lumicell Awarded Phase I NIH SBIR Contract to Develop Novel Flexible Endoscope for Fluorescence Imaging of LUMISIGHT™ to Detect Early Esophageal Lesions in Patients with Barrett’s Esophagus
Funding of approximately $400,000 will support development of novel endoscopic imaging platform combining far-red fluorescence and reflected light imaging to detect esophageal cancer NEWTON, Mass.,—Lumicell, Inc., a privately held company
CMS Grants Transitional Pass-Through Payment for LUMISIGHT™ (pegulicianine) and Increases Access for Patients with Breast Cancer
Transitional pass-through payment of optical imaging agent LUMISIGHT is effective October 1, 2024, as part of the hospital outpatient prospective payment system (OPPS) NEWTON, Mass.,—Lumicell, Inc., a privately held company
Lumicell Announces New Category III CPT® Code for Intraoperative Fluorescence Imaging Margin Assessment in Support of Market Launch
Add-on CPT code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ DVS, together referred to as LumiSystem™, with commercial availability in Q4 2024 NEWTON, Mass., July 15, 2024—Lumicell,
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer
LUMISIGHT™ and Lumicell™ Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from
Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting
Key Studies Examined the Benefits of Intraoperative Imaging Using Investigational Agent LUMISIGHT™ in Combination with Lumicell™ Direct Visualization System (DVS) NEWTON, Mass., March 25, 2024—Lumicell Inc., a privately held
Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT™ in the Detection of Cancerous Tissue During Breast Conserving Surgery
NEWTON, Massachusetts – Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer, today announced the Medical Imaging Drugs Advisory Committee (MIDAC) of the U.S Food
Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum
Promising feasibility study results for imaging technology that identified malignant peritoneal tumor metastasis during surgery NEWTON, Mass.–(BUSINESS WIRE)–Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies
Lumicell Co-Founder Moungi Bawendi Awarded Nobel Prize in Chemistry
Bawendi’s expertise in optics, fluorescent molecules and tissue imaging were instrumental in development of Lumicell Direct Visualization System, which is currently under FDA review NEWTON, Mass., October 5, 2023—Lumicell, Inc.,
Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for LUMISIGHT™ Optical Imaging Agent for Breast Cancer
NEWTON, Mass., May 22, 2023—Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced the U.S. Food and Drug Administration (FDA) has accepted
Events
San Antonio Breast Cancer Symposium®,
December 10-14, 2024
Henry B. Gonzalez Convention Center
Investors
